• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • NORTH AMERICA EDITION
      Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • NORTH AMERICA EDITION
      North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Theratechnologies Announces Financial Results for the Second Quarter of 2018

    Gabrielle Lakusta
    Jul. 05, 2018 08:27AM PST
    Pharmaceutical Investing

    Theratechnologies (TSX:TH) announced its financial results for the second quarter ended May 31, 2018. As quoted in the press release: “Although we are at a very early stage in the commercialization of Trogarzo™ in the U.S., we can appreciate the positive impact it is having on our bottom line. Given the positive response from patients, …

    Theratechnologies (TSX:TH) announced its financial results for the second quarter ended May 31, 2018.

    As quoted in the press release:

    “Although we are at a very early stage in the commercialization of Trogarzo™ in the U.S., we can appreciate the positive impact it is having on our bottom line. Given the positive response from patients, physicians and payers, Trogarzo™ sales are gradually picking up steam and we should continue to observe the benefits of our new product to our results,” said Luc Tanguay, President and CEO, Theratechnologies Inc.

    Second quarter 2018 financial results
    Consolidated revenue for the three- and six-month periods ended May 31, 2018 was $12,326,000 and $22,544,000 compared to $10,016,000 and $19,051,000 for the same periods ended May 31, 2017, an increase of 23.1% and 18.3% respectively. Revenue growth for the last quarter compared to the same quarter last year reflects the added contribution of Trogarzo™.

    Click here to read the full press release.

    pharmaceutical investingtsx:th
    The Conversation (0)

    Go Deeper

    AI Powered
    Canada maple leaves on left and pharmaceutical pills in red and blue on right.

    3 Best-performing Canadian Pharma Stocks (Updated August 2024)

    Iterum Reports Third Quarter 2018 Financial Results and Recent Highlights

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Cardiol Therapeutics

    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×